CASI Pharmaceuticals, Inc. (CASI)
NASDAQ: CASI · Real-Time Price · USD
2.100
-0.060 (-2.78%)
At close: Apr 1, 2025, 4:00 PM
2.233
+0.133 (6.33%)
After-hours: Apr 1, 2025, 4:28 PM EDT
CASI Pharmaceuticals Revenue
In the year 2024, CASI Pharmaceuticals had annual revenue of $28.54M, down -15.77%. CASI Pharmaceuticals had revenue of $13.36M in the quarter ending December 31, 2024, with 94.30% growth.
Revenue (ttm)
$28.54M
Revenue Growth
-15.77%
P/S Ratio
1.16
Revenue / Employee
$162,142
Employees
176
Market Cap
32.53M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.54M | -5.34M | -15.77% |
Dec 31, 2023 | 33.88M | -9.23M | -21.41% |
Dec 31, 2022 | 43.11M | 12.94M | 42.89% |
Dec 31, 2021 | 30.17M | 15.03M | 99.25% |
Dec 31, 2020 | 15.14M | 11.01M | 266.52% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
CASI News
- 1 day ago - CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results - Accesswire
- 3 months ago - CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - Accesswire
- 4 months ago - CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - Accesswire
- 5 months ago - CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - Accesswire
- 7 months ago - CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - PRNewsWire
- 8 months ago - CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2024 BUSINESS AND FINANCIAL RESULTS - PRNewsWire
- 9 months ago - CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS - PRNewsWire
- 9 months ago - CASI Pharmaceuticals announces appointment of Daniel Lang, MD as CFO and SVP - PRNewsWire